STAMFORD, Conn., Feb. 4, 2015 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company focused on the discovery, development, and commercialization of targeted cancer therapies, today announced that Joshua H. Bilenker, M.D., Chief Executive Officer will present a corporate overview at two upcoming conferences.
Details of the conferences are as follows:
- 2015 Leerink Global Healthcare Conference, February 11, 2015 at 3:05 pm ET, The Waldorf Astoria Hotel, New York, NY
- Cowen & Co. 35th Annual Health Care Conference, March 2, 2015 at 4:10 pm ET, The Boston Marriott Copley Place, Boston MA
Live webcasts of the presentations will be available at http://ir.loxooncology.com/.
About Loxo Oncology
Loxo Oncology is committed to the discovery, development, and commercialization of targeted cancer therapies with best-in-class potential. Our diverse pipeline reflects the convergence of proven therapeutic technologies with emerging insights into the underlying susceptibilities of cancer and drug resistance. We partner with leaders in academia and industry, allowing our management team to focus on clinical-regulatory execution in well-defined patient populations. www.loxooncology.com.
| Contacts |
| Company: |
| Jacob S. Van Naarden |
| Vice President, Corporate Development and Strategy |
| jake@loxooncology.com |
| Investors: |
| Peter Rahmer |
| The Trout Group, LLC |
| 646-378-2973 |
| prahmer@troutgroup.com |
| Media: |
| Karen Sharma |
| MacDougall Biomedical Communications |
| 781-235-3060 |
| ksharma@macbiocom.com |
Help employers find you! Check out all the jobs and post your resume.
